266 related articles for article (PubMed ID: 29567371)
1. A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: A role for Th17 cells in psychosis?
Vergaelen E; Schiweck C; Van Steeland K; Counotte J; Veling W; Swillen A; Drexhage H; Claes S
Brain Behav Immun; 2018 May; 70():88-95. PubMed ID: 29567371
[TBL] [Abstract][Full Text] [Related]
2. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
[TBL] [Abstract][Full Text] [Related]
3. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
[TBL] [Abstract][Full Text] [Related]
4. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
[TBL] [Abstract][Full Text] [Related]
5. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
[TBL] [Abstract][Full Text] [Related]
6. Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome - Clinical and scientific implications.
Mekori-Domachevsky E; Taler M; Weinberger R; Guri Y; Dar S; Shani S; Dekel I; Weizman A; Gothelf D
Schizophr Res; 2021 May; 231():164-169. PubMed ID: 33866261
[TBL] [Abstract][Full Text] [Related]
7. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome.
Schneider M; Van der Linden M; Menghetti S; Glaser B; Debbané M; Eliez S
J Psychiatr Res; 2014 Jan; 48(1):86-93. PubMed ID: 24189154
[TBL] [Abstract][Full Text] [Related]
8. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
[TBL] [Abstract][Full Text] [Related]
9. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
[TBL] [Abstract][Full Text] [Related]
10. Cognitive behavioral therapy in 22q11.2 microdeletion with psychotic symptoms: What do we learn from schizophrenia?
Demily C; Franck N
Eur J Med Genet; 2016 Nov; 59(11):596-603. PubMed ID: 27639442
[TBL] [Abstract][Full Text] [Related]
11. Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.
Niarchou M; Chawner SJRA; Fiksinski A; Vorstman JAS; Maeder J; Schneider M; Eliez S; Armando M; Pontillo M; Vicari S; McDonald-McGinn DM; Emanuel BS; Zackai EH; Bearden CE; Shashi V; Hooper SR; Owen MJ; Gur RE; Wray NR; van den Bree MBM; Thapar A;
Schizophr Res; 2019 Feb; 204():320-325. PubMed ID: 30093352
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis.
Provenzani U; Damiani S; Bersano I; Singh S; Moschillo A; Accinni T; Brondino N; Oliver D; Fusar-Poli P
Int Rev Psychiatry; 2022; 34(7-8):676-688. PubMed ID: 36786112
[TBL] [Abstract][Full Text] [Related]
13. Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
Van L; Boot E; Bassett AS
Curr Opin Psychiatry; 2017 May; 30(3):191-196. PubMed ID: 28230630
[TBL] [Abstract][Full Text] [Related]
14. Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome.
Taler M; Mekori-Domachevsky E; Vergaelen E; Claes S; Serur Y; Dar S; Levy-Shraga Y; Weizman A; Swillen A; Gothelf D
World J Biol Psychiatry; 2022 Jul; 23(6):475-482. PubMed ID: 34854358
[TBL] [Abstract][Full Text] [Related]
15. Attenuated positive symptoms of psychosis in adolescents with chromosome 22q11.2 deletion syndrome.
Stoddard J; Niendam T; Hendren R; Carter C; Simon TJ
Schizophr Res; 2010 May; 118(1-3):118-21. PubMed ID: 20056393
[TBL] [Abstract][Full Text] [Related]
16. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
[TBL] [Abstract][Full Text] [Related]
17. Inter-rater reliability of subthreshold psychotic symptoms in individuals with 22q11.2 deletion syndrome.
Moore TM; Salzer D; Bearden CE; Calkins ME; Kates WR; Kushan L; Gallagher RS; Frumer DS; Weinberger R; McDonald-McGinn DM; Gur RE; Gothelf D
J Neurodev Disord; 2021 Jun; 13(1):23. PubMed ID: 34126928
[TBL] [Abstract][Full Text] [Related]
18. White matter abnormalities in 22q11.2 deletion syndrome: preliminary associations with the Nogo-66 receptor gene and symptoms of psychosis.
Perlstein MD; Chohan MR; Coman IL; Antshel KM; Fremont WP; Gnirke MH; Kikinis Z; Middleton FA; Radoeva PD; Shenton ME; Kates WR
Schizophr Res; 2014 Jan; 152(1):117-23. PubMed ID: 24321711
[TBL] [Abstract][Full Text] [Related]
19. The dimensional structure of psychopathology in 22q11.2 Deletion Syndrome.
Niarchou M; Moore TM; Tang SX; Calkins ME; McDonald-McGuinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
J Psychiatr Res; 2017 Sep; 92():124-131. PubMed ID: 28433949
[TBL] [Abstract][Full Text] [Related]
20. Associations between neurodevelopmental genes, neuroanatomy, and ultra high risk symptoms of psychosis in 22q11.2 deletion syndrome.
Thompson CA; Karelis J; Middleton FA; Gentile K; Coman IL; Radoeva PD; Mehta R; Fremont WP; Antshel KM; Faraone SV; Kates WR
Am J Med Genet B Neuropsychiatr Genet; 2017 Apr; 174(3):295-314. PubMed ID: 28139055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
